

SUBJECT INDEX TO VOLUME 6

- Acarbose.** 6 (1): 40 – 43.
Acquired. 6 (4): 255 – 260.
Acquired. 6 (4): 289 – 292.
Actin. 6 (1): 49 – 53.
Analgesia. 6 (2): 81 – 85.
Anesthesia. 6 (2): 81 – 85.
Anomalies. 6 (4): 299 – 300.
Anterior Transposition. 6 (3): 200 – 203.
Antibody. 6 (1): 9 – 12.
Anxiety. 6 (2): 91 – 94.
Appendectomy. 6 (2): 107 – 110.
Appendicitis. 6 (2): 107 – 110.
Ardabil. 6 (3): 222 – 223.
Arteriovenous Malformation. 6 (1): 54 – 58.
Bacillus anthracis. 6 (4): 251 – 254.
Bed Occupancy Rate. 6 (3): 170 – 175.
Behavior. 6 (2): 95 – 102.
Bioequivalence. 6 (1): 44 – 48.
Borrelia. 6 (3): 222 – 223.
Botulinum Toxins. 6 (4): 265 – 268.
Boundaries. 6 (4): 243 – 250.
Breast Cancer. 6 (4): 273 – 277.
Burst Fracture. 6 (2): 103 – 106.
Cancer Susceptibility. 6 (4): 273 – 277.
Captopril Tablet. 6 (1): 44 – 48.
Carboplatin. 6 (3): 176 – 179.
Carcinoma. 6 (4): 278 – 281.
Cardiac Surgery. 6 (3): 170 – 175.
Carthamus tinctorius. 6 (2): 117 – 120.
Cauda Equina Syndrome. 6 (2): 146 – 148.
CD4/CD8 Ratio. 6 (3): 204 – 207.
Central Nervous Cyst. 6 (1): 59 – 62.
Cerebrovascular Accident. 6 (4): 265 – 268.
Comorbidity. 6 (3): 189 – 191.
Congenital. 6 (4): 289 – 292.
CVID. Common variable immunodeficiency, 6 (1): 16 – 22.
Cytoskeletal Structure. 6 (1): 49 – 53.
Depression. 6 (2): 91 – 94.
Diabetes Mellitus. 6 (1): 35 – 39; 6 (4): 237 – 242.
Diabetic Rats. 6 (1): 40 – 43.
Dipstick rK39. 6 (1): 29 – 31.
Dirofilaria repens. 6 (1): 63 – 65.
Dirofilariasis. 6 (1): 63 – 65.
Disseminated Peritoneal Leiomyomatosis. 6 (3): 216 – 218.
Docetaxel. 6 (3): 176 – 179.
Dog. 6 (1): 29 – 31.
Drainage. 6 (2): 107 – 110.
Drug Resistance. 6 (3): 192 – 195.
Drug Resistance. 6 (4): 255 – 260.
Efficacy. 6 (4): 269 – 272.
Effusion. 6 (4): 278 – 281.
Embryotoxicity. 6 (2): 117 – 120.
Endoderm. 6 (1): 59 – 62.
Entrogenous Cyst. 6 (1): 59 – 62.
Epicondylitis. 6 (3): 196 – 199.
Epidemiology. 6 (1): 5 – 8.
Epidural Morphine. 6 (2): 81 – 85.
Flumazenil. 6 (2): 111 – 116.
Gastric Emptying. 6 (3): 180 – 183.
Gastric Scintigraphy. 6 (3): 180 – 183.
Gastroesophageal Reflux Disease (GERD). 6 (3): 180 – 183.
Gastrointestinal Anthrax. 6 (4): 251 – 254.
Gastrointestinal. 6 (4): 261 – 264.
Glucose Tolerance Test. 6 (1): 35 – 39.
Growth Charts. 6 (3): 163 – 169.
GSTM₁. 6 (4): 273 – 277.
GSTT₁. 6 (4): 273 – 277.
HBV Vaccine. 6 (4): 269 – 272.
HBV. Hepatitis B Virus, 6 (1): 1 – 4; 6 (1): 9 – 12; 6 (4): 269 – 272.
HCV. Hepatitis B Virus, 6 (1): 1 – 4.
Head Circumference. 6 (3): 163 – 169.
Health Education. 6 (2): 95 – 102.
Health System. 6 (4): 243 – 250.
Heavy Ions (Fe or Ar). 6 (2): 121 – 126.
Height. 6 (3): 163 – 169.
Hemiplegia. 6 (4): 265 – 268.
Hereditary Complicated. 6 (4): 296 – 298.
Herpes Simplex. 6 (1): 13 – 15.
HIV Infection. 6 (4): 269 – 272.
HIV. Human Immunodeficiency Virus, 6 (1): 1 – 4; 6 (1): 5 – 8.
HLA Antigens. 6 (1): 16 – 22.
HLA Typing. 6 (1): 23 – 28.
HLA-A2. 6 (4): 282 – 288.
HLA-B7. 6 (4): 282 – 288.
Hospital. 6 (3): 170 – 175.
HPLC. High-performance liquid chromatographic, 6 (1): 44 – 48.
Human Serum. 6 (1): 44 – 48.
Human. 6 (1): 29 – 31.
Hyperlipidemia. 6 (1): 32 – 34.
Immunodeficiency. 6 (1): 16 – 22.
Immunology. 6 (1): 5 – 8.
Infection. 6 (1): 5 – 8.
Inferior Pblique Muscle. 6 (3): 200 – 203.
Infertility. 6 (4): 261 – 264.
Initial. 6 (4): 255 – 260.
Intercommunication. 6 (4): 299 – 300.
Intestinal Absorption. 6 (1): 40 – 43.
Intestinal Permeability. 6 (1): 49 – 53.
Intradermal. 6 (1): 9 – 12.
Intramuscular. 6 (1): 9 – 12.
Iran. 6 (1): 1 – 4; 6 (1): 29 – 31; 6 (3): 184 – 188.
Islet of Langerhans. 6 (1): 35 – 39.
IV drug users. 6 (1): 1 – 4.
Kaposi's Sarcoma. 6 (2): 143 – 145.
Kidney Transplantation. 6 (4): 293 – 295.
LDL Cholesterol. 6 (1): 32 – 34.
Leiomyoma. 6 (3): 216 – 218.
Ligation. 6 (2): 107 – 110.
Low Back Pain. 6 (2): 91 – 94.
Lumbar Disc Disease. 6 (2): 146 – 148.
Lung Surgery. 6 (2): 81 – 85.
Lymphocytotoxicity Test. 6 (1): 23 – 28.
Lymphoma. 6 (2): 143 – 145.
Lytic Function. 6 (4): 282 – 288.
Magnetic Resonance Imaging. MRI, 6 (2): 146 – 148.
Mechanism. 6 (1): 54 – 58.
Meningitis. 6 (3): 222 – 223.
Mental Health. 6 (2): 91 – 94.
Mesothelium. 6 (4): 278 – 281.
Methylprednisolone. 6 (3): 196 – 199.
Mice. 6 (2): 111 – 116.
Midezolam. 6 (2): 111 – 116.
Modeling. 6 (4): 243 – 250.
Mood Disorders. 6 (3): 189 – 191.
Natural Killer (NK) Cells. 6 (4): 282 – 288.
Neurenteric Cyst. 6 (1): 59 – 62.
Neurophysiology. 6 (4): 296 – 298.
Ovarian Cancer. 6 (3): 176 – 179.
p53. 6 (2): 121 – 126.
PARP. Poly (ADP-ribose) polymerase, 6 (2): 121 – 126.
Pathology. 6 (4): 261 – 264.
PCR. Polymerase chain reaction, 6 (1): 23 – 28.
Percentiles. 6 (3): 163 – 169.
Peritoneal. 6 (4): 261 – 264.
Pleural Effusion. 6 (3): 208 – 211.
Pneumococcus. 6 (3): 192 – 195.
Pneumothorax. 6 (3): 208 – 211.
Polynuropathy. 6 (4): 296 – 298.
Pregnancy. 6 (2): 146 – 148.
Psychiatric Patients. 6 (3): 184 – 188.
Psychosocial Evaluation. 6 (4): 293 – 295.
Punch Grafting. 6 (2): 86 – 90.
Ramadan Fasting. 6 (4): 238 – 243.
Rats. 6 (1): 35 – 39.
Reexpansion Pulmonary Edema (RPE). 6 (3): 208 – 211.
Renal Transplantation. 6 (2): 143 – 145.
Salivary Glands. 6 (4): 299 – 300.
Sarcoidosis. 6 (3): 204 – 207.
Seizure. 6 (3): 219 – 221.
Seminal Vesicle Cyst. 6 (4): 289 – 292.
Serotonin Receptor Antagonist. 6 (2): 111 – 116.
sHLA Class I. 6 (4): 282 – 288.
Sialoangiography (sialography). 6 (4): 299 – 300.
Sialosyl-Tn. 6 (4): 278 – 281.
Simulation. 6 (3): 170 – 175.
Smoking. 6 (2): 95 – 102.
Social Inoculation. 6 (2): 95 – 102.
Spastic Paraplegia. 6 (4): 296 – 298.
Spasticity. 6 (4): 265 – 268.
Spinal Canal. 6 (2): 103 – 106.
Spinal Cord Injury. 6 (2): 103 – 106.
Spontaneous Disappearance. 6 (1): 54 – 58.
Sporadic. 6 (4): 296 – 298.
Spouse. 6 (4): 293 – 295.
Streptococcus pneumoniae. 6 (3): 192 – 195.
Streptozocin. 6 (1): 40 – 43.
Subcutaneous Nodule. 6 (1): 63 – 65.
Substance Dependence. 6 (3): 189 – 191.
Superior Oblique Palsy. 6 (3):

Authors Index

200 – 203.

Superstition. 6 (3): 184 – 188.

Tail-Flick Test. 6 (2): 111 – 116.

Tehran. 6 (2): 95 – 102.

Tennis Elbow. 6 (3): 196 – 199.

Teratogenicity. 6 (2): 117 – 120.

Teucrium polium. 6 (1): 35 – 39.

Zinc Sulfate. 6 (1): 13 – 15.

Thrombosis. 6 (1): 54 – 58.

Topical PUVA. 6 (2): 86 – 90.

Topical Therapy. 6 (1): 13 – 15.

Torticollis. 6 (1): 59 – 62.

Triglycerides. 6 (1): 32 – 34.

Tuberculoma. 6 (3): 219 – 221.

Tuberculosis. 6 (3): 204 – 207; 6 (3): 219 – 221; 6 (4): 255 – 260; 6 (4): 261 – 264.

Tubulin. 6 (1): 49 – 53.

Unripe Grape Juice. 6 (1): 32 – 34.

Visceral Leishmaniasis. 6 (1): 29 – 31.

Vitiligo. 6 (2): 86 – 90.

Weight. 6 (3): 163 – 169.